Janus Henderson Group PLC grew its holdings in Agios Pharmaceuticals Inc (NASDAQ:AGIO) by 29.6% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 32,400 shares of the biopharmaceutical company’s stock after buying an additional 7,400 shares during the quarter. Janus Henderson Group PLC owned 0.06% of Agios Pharmaceuticals worth $2,729,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. BlackRock Inc. increased its position in shares of Agios Pharmaceuticals by 1.3% during the 2nd quarter. BlackRock Inc. now owns 3,248,251 shares of the biopharmaceutical company’s stock worth $273,601,000 after purchasing an additional 42,198 shares in the last quarter. Lord Abbett & CO. LLC increased its position in shares of Agios Pharmaceuticals by 175.8% during the 1st quarter. Lord Abbett & CO. LLC now owns 1,044,346 shares of the biopharmaceutical company’s stock worth $85,407,000 after purchasing an additional 665,684 shares in the last quarter. First Trust Advisors LP increased its position in shares of Agios Pharmaceuticals by 8.3% during the 2nd quarter. First Trust Advisors LP now owns 731,794 shares of the biopharmaceutical company’s stock worth $61,639,000 after purchasing an additional 56,038 shares in the last quarter. Alkeon Capital Management LLC increased its position in shares of Agios Pharmaceuticals by 30.7% during the 1st quarter. Alkeon Capital Management LLC now owns 668,789 shares of the biopharmaceutical company’s stock worth $54,694,000 after purchasing an additional 157,170 shares in the last quarter. Finally, Baillie Gifford & Co. increased its position in shares of Agios Pharmaceuticals by 7.6% during the 2nd quarter. Baillie Gifford & Co. now owns 626,603 shares of the biopharmaceutical company’s stock worth $52,779,000 after purchasing an additional 44,462 shares in the last quarter. Institutional investors own 93.63% of the company’s stock.

A number of equities research analysts have commented on AGIO shares. Canaccord Genuity reissued a “buy” rating and set a $90.00 price objective on shares of Agios Pharmaceuticals in a report on Wednesday, September 5th. Needham & Company LLC reissued a “buy” rating on shares of Agios Pharmaceuticals in a report on Thursday, August 2nd. Piper Jaffray Companies set a $125.00 price objective on shares of Agios Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 2nd. SunTrust Banks reissued a “buy” rating and set a $123.00 price objective on shares of Agios Pharmaceuticals in a report on Monday, July 23rd. Finally, BidaskClub lowered shares of Agios Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, June 26th. Six analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $96.27.

Shares of NASDAQ AGIO traded up $2.52 during mid-day trading on Friday, hitting $65.88. The company’s stock had a trading volume of 565,766 shares, compared to its average volume of 443,725. The firm has a market capitalization of $4.47 billion, a PE ratio of -9.76 and a beta of 1.73. Agios Pharmaceuticals Inc has a one year low of $51.62 and a one year high of $99.82.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($1.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.62) by $0.43. The company had revenue of $40.40 million for the quarter, compared to analyst estimates of $12.47 million. Agios Pharmaceuticals had a negative net margin of 462.08% and a negative return on equity of 51.71%. The company’s revenue for the quarter was up 257.5% on a year-over-year basis. During the same quarter last year, the firm earned ($1.78) EPS. As a group, equities research analysts expect that Agios Pharmaceuticals Inc will post -6.11 EPS for the current year.

In other news, insider Scott Biller sold 3,000 shares of the firm’s stock in a transaction dated Friday, October 5th. The shares were sold at an average price of $69.79, for a total value of $209,370.00. Following the transaction, the insider now owns 53,932 shares of the company’s stock, valued at approximately $3,763,914.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Christopher Bowden sold 1,700 shares of the firm’s stock in a transaction dated Thursday, August 30th. The shares were sold at an average price of $80.03, for a total transaction of $136,051.00. Following the completion of the transaction, the insider now directly owns 1,224 shares in the company, valued at approximately $97,956.72. The disclosure for this sale can be found here. Insiders sold a total of 28,355 shares of company stock worth $2,148,062 in the last ninety days. Insiders own 3.02% of the company’s stock.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.

Further Reading: Penny Stocks, What You Need To Know

Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.